This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Galit Kleiner-Fisman, MD, FRCPC; David N. Fisman, MD, MPH

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We thank Dr Tan for his interest in our recent publication.¹ We agree that variation in estimates of the prevalence of pedal edema in existing studies may result from variability in the ascertainment of edema, differences between study populations (in propensity to develop pedal edema in response to dopamine agonists and in background risk of edema due to other causes), and chance variation, particularly when small populations are studied. For example, Dr Tan reports an incidence of edema of 15% in his study population of 20 patients; the 95% confidence interval around this estimate is 3% to 39%! Methods for ascertaining whether variations between studies are due to random chance or true heterogeneity are described in the systematic review literature.² As we note in our article, our estimate of prevalence of edema is subject to all the limitations that . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Peripheral Edema and Dopamine Agonists in Parkinson Disease
Eng-King Tan
Arch Neurol. 2007;64(10):1546-1547.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Galit Kleiner-Fisman and David N. Fisman
Arch Neurol. 2007;64(6):820-824.
ABSTRACT | FULL TEXT